跳至主要内容
临床试验/NCT00914251
NCT00914251Unknown2 期

Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome

University of Rome Tor Vergata1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
30
试验地点
1
主要终点
Safety of oral supplementation of hesperidin

研究概览

简要总结

It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Metabolic Syndrome (ATPIII criteria)
  • Age 20-55

排除标准

  • History of cancer.
  • History of cardiovascular diseases.
  • Any other acute or chronic illness which requires administration of steroids or other drugs able to interfere with glucose or lipid metabolism.

研究组 & 干预措施

Hesperidin, 500 mg per day

Active Comparator

500 mg daily of oral Hesperidin for 3 weeks

干预措施: Hesperidin (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Safety of oral supplementation of hesperidin

时间窗: 3 weeks

次要结局

  • Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers.(3 weeks)

研究者

发起方
University of Rome Tor Vergata
申办方类型
Other

研究点 (1)

Loading locations...

相似试验